Retatrutide and trizepatide are a new class of medications that target both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These dual receptor agonists exhibit https://zoyaamkq734284.azzablog.com/39075574/novel-glp-1-and-gip-receptor-agonists-retatrutide-and-trizepatide